CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company, announced on Monday, that it has named Roger J Pomerantz, MD, FACP as its new chairman effective immediately.

Presently, Dr Pomerantz is the president, chief executive officer and chairman of the board of directors of ContraFect. Dr Pomerantz has extensive board experience and presently serves on the boards of Intec Pharma and VerImmune, in addition to ContraFect. He also serves as the chairman of the Scientific Advisory Board of Aridis Pharmaceuticals. He was also a Venture Partner at Flagship Pioneering from 2014 until 2019. Earlier, he served as the president, chief executive officer and chairman of the board of Seres Therapeutics, where he continues to serve as advisor. Prior to joining Seres, he was senior vice president, worldwide head of Licensing & Acquisition at Merck & Co Inc and prior to that was senior vice president and global franchise head of Infectious Diseases at Merck. Prior to joining Merck, he was global head of Infectious Diseases for Johnson & Johnson Pharmaceuticals.

Yehiel Tal, CollPlant chief executive officer, said, 'Dr Pomerantz's extensive knowledge of the life science industry as a clinician, senior executive and board member is exactly what we need as we bolster our strategic partnerships and clinical development efforts for our recombinant human collagen (rhCollagen) technology platform. Roger is an excellent addition to our team and will play an integral role in our mission to provide optimal treatment options for patients through ground-breaking solutions in the field of regenerative and aesthetic medicine.'